13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • SBP-CL-101-03

    Acronym: 

    SBP-CL-101-03

    ACTRN/NCT /ethics: 

    NCT03412799

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Pancreas
    Trial Type Treatment
    Phase Phase I Tumour Stream Pancreas
    Age Range 18 years and older Cancer Stage Metastatic or Widespread
    Sex Both Anticipated Start Date 2018-06-04
    Molecular Target Anticipated End Date
    Cancer Type Pancreas
    Trial Type Treatment
    Phase Phase I
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Pancreas
    Cancer Stage Metastatic or Widespread
    Anticipated Start Date 2018-06-04
    Anticipated End Date

    Trial Summary

    A Phase 1a/1b Dose Escalation and Expansion Study of SBP-101 in Combination with Nab-Paclitaxel and gemcitabine in subjects with previously untreated metastatic pancreatic ductal adenocarcinoma

    Lay Summary

    Sponsor / Cooperative group

    Sun BioPharma Inc

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Ashford Cancer Centre Research Helen Daykin hdaykin@adelaidecancercentre.com.au 08 8292 2240 Recruiting